Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vox Sang ; 59(3): 153-9, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2264318

RESUMEN

We provide a detailed description of a new method for counting very low numbers of leukocytes present in platelet products. The method uses fluorescent staining of leukocyte DNA using propidium iodide and flow cytometry. The assay is accurate over a range of leukocyte concentrations from 0.1 to 10 WBC/microliter. We validated the method using specially designed dilution studies and applied it to the measurement of leukocyte content in leukocyte-depleted platelet products prepared by apheresis or filtration. This method should prove useful in studies which address the clinical impact of leukocyte-depleted platelet products.


Asunto(s)
Plaquetas , Separación Celular/métodos , Citometría de Flujo/métodos , Recuento de Leucocitos/métodos , Humanos
2.
Transfusion ; 31(6): 542-6, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1853450

RESUMEN

This article introduces a new method of component preparation that is capable of producing white cell (WBC)-reduced platelet concentrates (PCs) from whole blood. Whole blood is separated into packed red cells (RBCs) and platelet-rich plasma (PRP) by centrifugation, and the PRP is expressed through a newly designed WBC removal filter into the platelet storage bag. The filtered PRP is then centrifuged and yields WBC-reduced PCs and plasma for freezing as fresh-frozen plasma (FFP). The method uses standard triple-pack blood bags and centrifugation protocols. Fifteen WBC-reduced PCs prepared with this technique had an average volume of 56.7 mL, an average Day 5 platelet content of 8.6 x 10(10) per unit, and an average Day 5 WBC content of 0.83 +/- 0.7 x 10(4) per unit (0.14 WBCs/microL). This represents WBC removal equal to at least 99.9 percent (3 log10) of the WBCs found in standard PCs prepared in our laboratory by an identical centrifugation protocol. Paired studies documented a 4.5-percent platelet loss by filtration. Filtration had no effect on the plasma prepared for FFP as measured by prothrombin time; activated partial thromboplastin time; factors I, V, VIII:C, and VIII:von Willebrand factor; antithrombin-III; albumin; globulin; or total protein. This method holds promise as a simple and highly effective technique for the production of WBC-reduced PCs by filtration during component preparation.


Asunto(s)
Plaquetas , Leucaféresis , Filtración , Humanos , Métodos
3.
Transfusion ; 32(4): 334-9, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1585438

RESUMEN

The role of residual donor white cells (WBCs) in producing the storage lesion of platelets used for transfusion was studied. The effect of prestorage WBC reduction on in vitro and in vivo measurements of the quality of stored platelet concentrates (PCs) was examined by using a newly developed WBC-reduction filter capable of preparing PCs with a mean residual WBC concentration of less than 1 per microL. For in vitro studies, a triplet study design was used, in which WBC-reduced PCs were matched to standard PCs and to WBC-enriched PCs obtained from the same donor at the same phlebotomy. Twelve donors were studied. Prestorage WBC reduction resulted in a higher pH and pO2 and a lower pCO2 than in standard PCs. In accord with previous in vitro studies, a significant rise in plasma glycocalicin and lactate dehydrogenase was measured during storage, but the levels were not significantly different in WBC-reduced PCs and standard PCs. Platelet aggregation and ATP release in response to graded doses of thrombin was similar in WBC-reduced and standard PCs. In vivo recovery and survival studies were comparable in WBC-reduced and standard PCs. Although the residual donor WBC content of PCs has a significant impact on storage pH, pO2, and pCO2, prestorage WBC reduction does not affect platelet structure, function, or viability as assessed by in vitro or in vivo measurements.


Asunto(s)
Plaquetas/citología , Conservación de la Sangre , Recuento de Leucocitos , Complejo GPIb-IX de Glicoproteína Plaquetaria , Adenosina Trifosfato/metabolismo , Plaquetas/fisiología , Supervivencia Celular , Humanos , Concentración de Iones de Hidrógeno , Radioisótopos de Indio , L-Lactato Deshidrogenasa/sangre , Agregación Plaquetaria , Recuento de Plaquetas , Glicoproteínas de Membrana Plaquetaria/análisis
4.
J Immunol ; 166(9): 5585-93, 2001 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-11313398

RESUMEN

A20 IIA1.6 B cells cotransfected with FcalphaR and wild-type gamma-chain (wt-ITAM (immunoreceptor tyrosine-based activation motif)) or FcalphaR and gamma-chain, in which the wt-ITAM was substituted with the FcgammaRIIA ITAM (IIA-ITAM), were used to investigate cell signaling events influencing presentation of FcalphaR-targeted exogenous Ag in the context of MHC class II. wt-ITAM cells presented FcalphaR-targeted OVA more efficiently than IIA-ITAM transfectants to OVA-specific T cell hybridomas. Phosphatidylinositol 3-kinase (PI 3-kinase) inhibition abrogated Ag presentation, suggesting that FcalphaR may trigger a PI 3-kinase-dependent signal transduction pathway, and thus phosphatidylinositol-dependent protein kinase (PDK1) and protein kinase B alpha (PKBalpha) activation. Cross-linking FcalphaR on wt-ITAM or IIA-ITAM cells triggered equivalent PI 3-kinase-dependent activation of PKBalpha. Furthermore, FcalphaR cross-linking triggered recruitment of PDK1 and serine-phosphorylated PKBalpha to capped cell surface FcalphaR irrespective of the gamma-chain ITAM. Although FcalphaR endocytosis was accompanied by translocation of PDK1 and phospho-PKBalpha to FcalphaR-containing vesicles in both transfectants, this was decreased in IIA-ITAM cells, and a significant proportion of PDK1 and PKBalpha remained at the plasma membrane. In wt-ITAM cells, PDK1 and serine-phosphorylated PKBalpha translocated to lysosomal-associated membrane glycoprotein 1- and cathepsin B-containing vesicles, consistent with MHC class II peptide-loading compartments (MIIC) described by other groups. Our data indicate that translocation of signal transduction mediators to MIIC-like compartments accompanies efficient presentation of receptor-targeted Ag, and suggest a mechanism connecting signaling to the Ag-processing pathway.


Asunto(s)
Antígenos CD/inmunología , Antígenos CD/metabolismo , Antígenos de Histocompatibilidad Clase II/metabolismo , Inmunoglobulina A/metabolismo , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas , Receptores Fc/inmunología , Receptores Fc/metabolismo , Proteínas Quinasas Dependientes de 3-Fosfoinosítido , Secuencias de Aminoácidos , Secuencia de Aminoácidos , Animales , Presentación de Antígeno/genética , Antígenos CD/genética , Transporte Biológico Activo/genética , Transporte Biológico Activo/inmunología , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Línea Celular , Células Cultivadas , Cromonas/farmacología , Activación Enzimática/efectos de los fármacos , Activación Enzimática/inmunología , Inhibidores Enzimáticos/farmacología , Antígenos de Histocompatibilidad Clase II/sangre , Humanos , Hibridomas , Activación de Linfocitos/genética , Ratones , Datos de Secuencia Molecular , Monocitos/enzimología , Monocitos/inmunología , Monocitos/metabolismo , Morfolinas/farmacología , Ovalbúmina/inmunología , Ovalbúmina/metabolismo , Fragmentos de Péptidos/sangre , Fosfatidilinositol 3-Quinasas/fisiología , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosforilación , Proteínas Serina-Treonina Quinasas/sangre , Proteínas Serina-Treonina Quinasas/genética , Proteínas Proto-Oncogénicas c-akt , Receptores Fc/genética , Receptores Inmunológicos/genética , Transfección , Tirosina/genética , Tirosina/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA